Asensus Surgical Inc

Asensus Surgical — TransEnterix — IPO Roadshow (April 2014)

30 slides from Asensus Surgical's IPO roadshow presentation, Apr 2, 2014

  1. Slide 1: Todd M. Pope, President & CEO; Joe Slattery, EVP & CFO

    Todd M. Pope, President & CE O Joe Slattery, EVP & CFO April 2, 2014 Exhibit 99.1

  2. Slide 2: Cautionary Statement

    2 Cautionary Statement Any statements contained in this presentation that do not describe historical facts, including statements about the beliefs and expectations of TransEnterix, Inc. (“TransEnterix,” "we" or "our"), may constitute forward-looking statements as that term is defined by the United S

  3. Slide 3: Advancing Surgery Through Innovation

    Advancing Surgery Through Innovation

  4. Slide 4: Transaction Overview

    4 Transaction Overview Issuer: TransEnterix, Inc. Ticker (Exchange): TRXC (NYSE MKT) (1) Amount Offered: $50 million Over-Allotment Option: 15% Lock-up Provision: 90 days Expected Pricing: April 10, 2014 Bookrunners: Stifel / RBC Capital Markets Use of Proceeds: For research and development, sales a

  5. Slide 5: Investment Highlights

    Investment Highlights 5 The SurgiBot System is currently under development Technology Focus Solution Market Experience • Surgical robotics • Developing patient-side robotic platform: SurgiBot • Addresses unmet needs in today’s robotic offerings • Cost effective • Broad procedure applicability • Larg

  6. Slide 6: Company History

    6 2006 2009 2010 2012 2013 Company History • TransEnterix founded • FDA 510(K) clearance for Spider Surgical System • CE Mark clearance and release of Spider Surgical System • >3,500 SPIDER cumulative procedures performed to date • Began SurgiBot development • SurgiBot preclinical labs

  7. Slide 7: Surgical Progress = Less Invasive

    7 Surgical Progress = Less Invasive Open Surgery Rigid Laparoscopy (1989) Flexible Laparoscopy (2010)

  8. Slide 8: Spider Surgical System Enabling Flexible Laparoscopy

    8 Spider Surgical System Enabling Flexible Laparoscopy • Internal (intra-abdominal) triangulation • Flexible, articulating instruments for dissection and retraction • True left/right instrumentation • Lower profile port of access • Over 3,500 procedures performed • Broad procedural mix

  9. Slide 9: SurgiBot

    SurgiBot Powered and Robotically-enabled Next-generation Platform* *The SurgiBot System is currently under development TM

  10. Slide 10: Benefits of Surgical Robotics

    10 Benefits of Surgical Robotics Improved dissection and retraction strength Enhanced precision and control Improved surgeon ergonomics Advanced visualization Benefits of Surgical Robotics

  11. Slide 11: Worldwide daVinci Procedures

    11 Worldwide daVinci Procedures Source: ISRG Investor Presentation, 2/21/2014

  12. Slide 12: Multi-Port SurgiBot Purpose Built for Abdominal Surgery

    12 The SurgiBot System is currently under development Multi-Port SurgiBot Purpose Built for Abdominal Surgery (2) ISRG investor call, 1/23/2014 (1) (1) Surgeon scrubbed-in Multi-quadrant utility Reduced incisions Internal triangulation Articulating instruments Space for assistant Cost ~$1.5M (2) ~$5

  13. Slide 13: SurgiBot First Patient-side Robotic Platform

    13 The SurgiBot System is currently under development Surgeon scrubbed-in Easily repositioned for multi- quadrant surgery Flexible, articulating channels & instruments Steerable 3DHD Small, mobile platform Cost effective platform SurgiBot First Patient-side Robotic Platform

  14. Slide 14: SurgiBot First Patient-side Robotic Platform

    14 The SurgiBot System is currently under development SurgiBot First Patient-side Robotic Platform 3DHD Optics/Cart SurgiBot

  15. Slide 15: SurgiBot Prototype Video

    15 The SurgiBot System is currently under development [Video of SurgiBot System Prototype] SurgiBot First Patient-side Robotic Platform

  16. Slide 16: Procedure Market Opportunity

    16 Procedure Market Opportunity Bariatric Surgery Cholecystectomy Colorectal Gynecology/Urology Targeted US Procedures 160K 1,140K 363K 230K ~2M US Laparoscopic Procedures Source: Millennium Research Group US Markets Laparoscopic Devices 2014

  17. Slide 17: Large Addressable Market

    Large Addressable Market 17 1,566 2,054 930 458 Source: CDC Over 5,000 Hospitals in the United States # of Beds Under 50 50-200 - Over 400

  18. Slide 18: Hospital Market Opportunity

    18 Hospitals without Robotic Capability Hospitals with Robotic Capability Hospital Market Opportunity • Invested in the strategic and competitive value of robotic surgery • ROI expectations changing/under pressure • Potential for diversification of robotic solutions • Procedures • Price • Facilities

  19. Slide 19: Significant Base of Underserved Hospitals

    Significant Base of Underserved Hospitals 19 Mid/Small Hospitals Surgery Centers • >3,000 w/ <300 beds • >80% lack robotic offering • Losing market share to robotic facilities • Represent >800K target annual procedures • ~5,000 in US • Economics driving rapid procedure growth • SurgiBot will offer v

  20. Slide 20: Combining Advanced Technology AND Maximizing Value

    20 Combining Advanced Technology AND Maximizing Value Price Traditional Laparoscopy >$10B Revenue Low Growth Surgical Robotics >$2B Revenue High Growth

  21. Slide 21: Highlights – Instrumentation

    21 Highlights – Instrumentation Instrumentation Needs By Procedure Status The SurgiBot System is currently under development Chole Bariatrics GYN SPIDER SurgiBot Grasper Launched Developed Dissector Launched Developed Hook Launched Developed Clip Applier Launched Developed Shears Launched Developed

  22. Slide 22: Operating Capabilities & Talent

    Operating Capabilities & Talent 22 Rapid Prototyping R&D Team Broad Experience cGMP Manufacturing

  23. Slide 23: Management Team

    Management Team 23 Prior Experience Todd M. Pope President and Chief Executive Officer Joe Slattery EVP and Chief Financial Officer Richard Mueller Chief Operating Officer Mohan Nathan Vice President of Global Marketing Tammy Carrea Vice President, Quality and Regulatory Affairs Nicole Bell Vice Pre

  24. Slide 24: Board of Directors and Healthcare Investors

    24 Board of Directors and Healthcare Investors Board of Directors Healthcare Investors • Phillip Frost, M.D. – CEO and Chairman of OPKO Health – Chairman of Teva Pharmaceuticals • Jane Hsiao, Ph.D., MBA – Former Chairman of SafeStitch – Vice Chairman and CTO of OPKO Health • Aftab Kherani, M.D. – Pr

  25. Slide 25: Regulatory Strategy

    Regulatory Strategy 25 2013 2014 2015 • 510(k) pathway • General intended use for laparoscopic abdominal access • Design & Pre-clinical Testing • Pre-submission FDA Meeting • Regulatory Clearances • Global Launch • First Human Procedures • Regulatory Submissions

  26. Slide 26: Financial Information

    Financial Information

  27. Slide 27: Recurring Revenue Model

    Recurring Revenue Model 27 Instruments and Accessories Service Capital Equipment The SurgiBot System is currently under development US Pricing: • Market-specific pricing • Distributors provide service/support International: • Capital sale ~$500K • Instruments ~$1,000-1,500/procedure • Service ~$50K/

  28. Slide 28: Financial Highlights

    Financial Highlights 28 The SurgiBot System is currently under development • Cash – Balance at 12/31/2013 $16.2M – Q4 ‘13 burn $8.7M, incl. $0.9M debt service and $0.7M capital equipment • Capital Sales Reps – Hire 5-8 early 2015 – ~15 by launch – ~30 to cover US – Supported by clinical and field se

  29. Slide 29: 2014 Key Objectives

    2014 Key Objectives 29 • FDA Pre-filing Submission - Q1 • Launch Flexible Advanced Energy Device - Q2 • Clinical SurgiBot Cases Begin - Q3 • SurgiBot FDA/CE Filings - Q4 Completed

  30. Slide 30: Investment Highlights

    Focus Technology Solution Market Experience Investment Highlights 30 The SurgiBot System is currently under development • Surgical robotics • Developing patient-side robotic platform: SurgiBot • Addresses unmet needs in today’s robotic offerings • Cost effective • Broad procedure applicability • Lar

TransEnterix — IPO Roadshow (April 2014) on 6ix